Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [7869]

Adoptive cell therapy plus checkpoint inhibitors show promise in non-small cell lung cancer

Adoptive cell therapy plus checkpoint inhibitors show promise in non-small cell lung cancer

Human epidermal growth-factor receptor predicts long term outcomes in ductal carcinoma in situ

Human epidermal growth-factor receptor predicts long term outcomes in ductal carcinoma in situ

Ultrasound remotely triggers immune cells to attack tumours in mice without toxic side effects

Ultrasound remotely triggers immune cells to attack tumours in mice without toxic side effects

Researchers pinpoint how PARP inhibitors combat BRCA1 and BRCA2 tumour cells

Researchers pinpoint how PARP inhibitors combat BRCA1 and BRCA2 tumour cells

Statins may improve survival for triple-negative breast cancer patients

Statins may improve survival for triple-negative breast cancer patients

Negative trade-off between neoantigen repertoire breadth and the specificity of HLA-I molecules shapes antitumour immunity

Negative trade-off between neoantigen repertoire breadth and the specificity of HLA-I molecules shapes antitumour...

FDA approves pembrolizumab for high-risk early-stage triple-negative breast cancer

FDA approves pembrolizumab for high-risk early-stage triple-negative breast cancer

Phase two CD19-antibody-drug conjugate trial demonstrates promise for aggressive lymphoma

Phase two CD19-antibody-drug conjugate trial demonstrates promise for aggressive lymphoma

Novel agent MS21 has potential in several cancers

Novel agent MS21 has potential in several cancers

FDA grants regular approval to pembrolizumab and lenvatinib for advanced endometrial carcinoma

FDA grants regular approval to pembrolizumab and lenvatinib for advanced endometrial carcinoma

More from ecancer